PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
about
Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspiratesThe forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyNovel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTORTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayTargeting disease through novel pathways of apoptosis and autophagyClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerShedding new light on neurodegenerative diseases through the mammalian target of rapamycinTargeted therapies in development for non-small cell lung cancermTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling AxisPIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life ExpectancyMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentChemoresistance and targeted therapies in ovarian and endometrial cancersGrb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancerPhosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitorsA genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingUnique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsPhase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.Synergistic interactions with PI3K inhibition that induce apoptosis.Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancerAnastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyClinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.The inhibitory effect of PIK-75 on inflammatory mediator response induced by hydrogen peroxide in feline esophageal epithelial cellsTP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
P2860
Q24564079-86A2F997-6DCE-4E06-AB10-D7428529087EQ26744087-58D50469-08D7-4E5C-AA54-F53947BF941BQ26749047-60808C20-1F0A-41CE-A098-98B0625F1EA0Q26750649-F3E2A89F-A854-49FF-8BA7-78D1F8DB58A9Q26825780-BDB22D23-00AF-45FC-8B38-76774377FE3DQ26864639-A096F51C-1399-4695-82A0-D0B3B71357FCQ27001170-C4042550-FE2E-4898-8514-8DDAD5FF22ACQ27015640-8F29B477-4D2E-4A00-B038-A6F3C13D3EAAQ27022852-3E9DFA77-9076-472E-A9EE-D198A2EC6548Q27310985-45EF24CD-21FC-414C-92FB-DC2810275778Q27852473-D27267BF-9B25-4B97-BC2A-9D84B7D171C7Q27852608-83035D68-5050-49C3-968A-B8328C74F7C8Q27853151-953D9D33-8BD5-49CD-B76B-50EEC256F092Q28066377-0BC1D01D-0300-4666-9D98-427B5884242DQ28066904-60CEBFE8-2AAE-443C-9001-A8B5D48D088CQ28073246-20AC3141-42A9-4146-A2D0-920218EED551Q28389726-DB9ED7A2-4DD6-4954-8A18-A0F04ED642F9Q30620482-C427B2B6-2418-49E8-93DE-E21FDFCBD41DQ31006978-5D75DFEA-EDAF-4D98-BB0A-016126054B83Q33414685-25D1FFA2-1737-48DF-B8F3-1FE4240D5C53Q33422258-C81E6BD1-2821-4C84-9F57-4C6262F5E5BDQ33435113-E6CF8ED9-D1C3-4AE3-BCAF-9AB54EC7A34DQ33684887-2CDF7FFC-4A7A-4DBC-89C9-353B8BB014A0Q33709537-88CE2A3C-E610-4055-9F31-796BF308D482Q33716499-4C0485FF-6A7C-4C4E-BCE2-DCB36AFED0DCQ33756991-C11BD56E-1FB7-44F6-B3ED-E331F1E081F8Q33810494-7742BC11-0911-41CC-B355-89E7DFED485DQ33822197-25FC54D4-2362-416F-8A8F-21B84759B42EQ33845387-5ECF051B-FB8B-4E94-827C-33F2739630FDQ33858387-07945520-91FC-4F0B-9C3B-49759DC7E660Q33862290-80FB6511-CBD7-4D84-911A-9B1BEF6672AEQ33917551-3FE146D9-4D3F-4D55-BAE4-45FC075D7C3FQ33937368-BB00368B-EAC3-4947-846F-F947E5F3DD90Q34033475-E516BA67-3192-4D61-BF84-3D2EF5201878Q34074997-93AF2987-3FF8-4563-8D56-39D1FAA3586CQ34147910-2A8B7F6C-CC18-44AD-B96F-D8AE38123D27Q34153696-F8F4F2B5-5F3A-42FF-8A97-09DCAF97F40FQ34222253-0A4BBE06-6FA8-4FD3-9F1D-A9DA53CAEE3CQ34239911-C3BD1BB4-E4A8-42F2-BAAE-BDF35AF122B3Q34295425-ADDDEA4B-D2D3-4397-A786-5D6A43C7012A
P2860
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@ast
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@en
type
label
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@ast
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@en
prefLabel
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@ast
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@en
P2093
P2860
P50
P356
P1476
PI3K/AKT/mTOR inhibitors in pa ...... es harboring PIK3CA mutations.
@en
P2093
David S Hong
Gerald S Falchook
J Jack Lee
Jennifer J Wheler
Karen H Lu
Rajyalakshmi Luthra
Shannon N Westin
Stacy L Moulder
P2860
P304
P356
10.1200/JCO.2011.36.1196
P407
P577
2012-01-23T00:00:00Z